Neuroprotection achieved in the ischaemic rat cortex with L-kynurenine sulphate
- PMID: 18387638
- DOI: 10.1016/j.lfs.2008.02.014
Neuroprotection achieved in the ischaemic rat cortex with L-kynurenine sulphate
Abstract
L-kynurenine is a metabolic precursor of kynurenic acid, which is one of the few known endogenous N-methyl-D-aspartate receptor inhibitors. In contrast with kynurenic acid, L-kynurenine is transported across the blood-brain barrier, and it may therefore come into consideration as a therapeutic agent in certain neurobiological disorders, e.g. ischaemia-induced events. The present study evaluated the effect of L-kynurenine administration (300 mg/kg i.p.) on the global ischaemic brain cortex both pre- and post-ischemic intervention. The statistical evaluation revealed that L-kynurenine administration beneficially decreased the number of neurones injured per mm(2) in the cortex, not only in the pre-treated animals, but also in those which received L-kynurenine after the ischaemic insult. It is concluded that even the post-traumatic administration of L-kynurenine may be of substantial therapeutic benefit in the treatment of global brain ischaemia. This is the first histological proof of the neuroprotective effect achieved by the post-traumatic administration of L-kynurenine in the global ischaemic cortex.
Similar articles
-
Neuroprotective effects of L-kynurenine on hypoxia-ischemia and NMDA lesions in neonatal rats.J Cereb Blood Flow Metab. 1992 May;12(3):400-7. doi: 10.1038/jcbfm.1992.57. J Cereb Blood Flow Metab. 1992. PMID: 1569135
-
Neuroprotective effect of L-kynurenine sulfate administered before focal cerebral ischemia in mice and global cerebral ischemia in gerbils.Eur J Pharmacol. 2007 Jun 14;564(1-3):116-22. doi: 10.1016/j.ejphar.2007.02.029. Epub 2007 Feb 23. Eur J Pharmacol. 2007. PMID: 17407777
-
Kynurenine administered together with probenecid markedly inhibits pentylenetetrazol-induced seizures. An electrophysiological and behavioural study.Neuropharmacology. 2004 Nov;47(6):916-25. doi: 10.1016/j.neuropharm.2004.06.007. Neuropharmacology. 2004. PMID: 15527825
-
The role of kynurenines in disorders of the central nervous system: possibilities for neuroprotection.J Neurol Sci. 2009 Aug 15;283(1-2):21-7. doi: 10.1016/j.jns.2009.02.326. Epub 2009 Mar 5. J Neurol Sci. 2009. PMID: 19268309 Review.
-
Mitochondrial disturbances, excitotoxicity, neuroinflammation and kynurenines: novel therapeutic strategies for neurodegenerative disorders.J Neurol Sci. 2012 Nov 15;322(1-2):187-91. doi: 10.1016/j.jns.2012.06.004. Epub 2012 Jun 27. J Neurol Sci. 2012. PMID: 22749004 Review.
Cited by
-
Kynurenic Acid/AhR Signaling at the Junction of Inflammation and Cardiovascular Diseases.Int J Mol Sci. 2024 Jun 25;25(13):6933. doi: 10.3390/ijms25136933. Int J Mol Sci. 2024. PMID: 39000041 Free PMC article. Review.
-
The Kynurenine Pathway in the Acute and Chronic Phases of Cerebral Ischemia.Curr Pharm Des. 2016;22(8):1060-73. doi: 10.2174/1381612822666151214125950. Curr Pharm Des. 2016. PMID: 25248805 Free PMC article. Review.
-
Altered hippocampal plasticity by prenatal kynurenine administration, kynurenine-3-monoxygenase (KMO) deletion or galantamine.Neuroscience. 2015 Dec 3;310:91-105. doi: 10.1016/j.neuroscience.2015.09.022. Epub 2015 Sep 10. Neuroscience. 2015. PMID: 26365611 Free PMC article.
-
Differential Effects of Hypothermia and SZR72 on Cerebral Kynurenine and Kynurenic Acid in a Piglet Model of Hypoxic-Ischemic Encephalopathy.Int J Mol Sci. 2023 Sep 25;24(19):14522. doi: 10.3390/ijms241914522. Int J Mol Sci. 2023. PMID: 37833970 Free PMC article.
-
Vascular expression, activity and function of indoleamine 2,3-dioxygenase-1 following cerebral ischaemia-reperfusion in mice.Naunyn Schmiedebergs Arch Pharmacol. 2011 May;383(5):471-81. doi: 10.1007/s00210-011-0611-4. Epub 2011 Feb 27. Naunyn Schmiedebergs Arch Pharmacol. 2011. PMID: 21359968
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources